

Quick reference guide

Pemetrexed for the treatment of malignant pleural mesothelioma

Guidance

- 1 Pemetrexed is recommended as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organization (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate.
- 2 Patients currently receiving pemetrexed who do not fall into the patient population defined in section 1 should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Implementation tools

NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website (www.nice.org.uk/TA135).

- A costing statement explaining the resource impact of this guidance.
- Audit criteria to monitor local practice.

Further information

Ordering information

You can download the following documents from www.nice.org.uk/TA135

- A quick reference guide (this document) – a summary of recommendations for healthcare professionals.
- 'Understanding NICE guidance' – information for patients and carers.
- The full guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or 'Understanding NICE guidance', phone the NHS Response Line on 0870 1555 455 and quote:

- N1454 (quick reference guide)
- N1455 ('Understanding NICE guidance').

Related NICE guidance

There is no related guidance for this technology.

Updating the appraisal

This technology appraisal will be considered for review in September 2010. Information about the progress of a review will be posted on the NICE website (www.nice.org.uk/TA135)

NICE technology appraisal guidance 135

This guidance represents the view of the Institute, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

NICE technology appraisal guidance is about the use of new and existing medicines and treatments in the NHS in England and Wales.



Published by the National Institute for Health and Clinical Excellence, 2008; ISBN 1-84629-588-2

© National Institute for Health and Clinical Excellence, 2008. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.